THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
THE PRIORITIZE STUDY: Study of Oral Regimens for Hepatitis C
Sponsor: University of Florida
Enrolling: Male and Female Patients
IRB Number: AAAQ8487
U.S. Govt. ID: NCT02786537
Contact: Elizabeth Verna MD: 212-305-0914 / ev77@cumc.columbia.edu
Additional Study Information: This study will compare the effectiveness of three different FDA approved medicines for Hepatitis C Genotype 1 patients: HARVONI , Viekira Pak and Zepatier and will observe subject experiences before, during, and after HCV treatment. Subjects will be asked to respond to several survey questionnaires and if they would allow their leftover blood collected for resistance testing during screening to be used for future research.
This study is closed
Investigator
Elizabeth Verna, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with Hepatitis C? Yes No
Are you pregnant or breastfeeding? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Elizabeth Verna MD
ev77@cumc.columbia.edu
212-305-0914
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE